IL-17A Increases Multiple Myeloma Cell Viability by Positively Regulating Syk Expression

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Elevated Interleukin-17 (IL-17) from T helper 17 (Th17) cells promotes multiple myeloma (MM) growth and immune suppression.
• IL-17A enhances MM cell growth and adhesion via IL-17 receptors and bone marrow stromal cells (BMSCs).
• Spleen tyrosine kinase (Syk) is implicated in MM cell survival and migration.

Purpose of the Study:

• To investigate the role of Syk in IL-17A-mediated regulation of MM cell viability.
• To elucidate the signaling pathways involved in IL-17A's effect on MM cells.

Main Methods:

• Cell viability assessed using CCK8 assay.
• Cytokine production (IL-17A) measured by ELISA.
• Protein expression (Syk, NF-κB molecules) analyzed by Western blotting.
• mRNA expression of RORγt determined by RT-qPCR.

Main Results:

• IL-17A is highly expressed in MM patients and increases MM cell viability.
• IL-17A's effects are mediated by the Syk/NF-κB signaling pathway.
• Syk is involved in IL-17A-induced Act1-TRAF6 complex formation and TRAF6 polyubiquitination.

Conclusions:

• IL-17A enhances MM cell viability by activating the NF-κB pathway through Syk upregulation.
• Syk is crucial for IL-17A-mediated NF-κB activation via the IL-17R-Act1-TRAF6 complex.
• Syk inhibition presents a potential therapeutic strategy for MM and other neoplastic diseases.